![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KALA BIO Inc | NASDAQ:KALA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.07 | 6.75 | 7.35 | 0 | 12:00:03 |
|
TABLE OF CONTENTS
|
| | |||||
| PROSPECTUS SUPPLEMENT | | | |||||
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-4 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-11 | | | |
| | | | | S-13 | | | |
| | | | | S-17 | | | |
| | | | | S-19 | | | |
| | | | | S-19 | | | |
| | | | | S-20 | | | |
| | | | | S-21 | | | |
| PROSPECTUS | | | | | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 15 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 30 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 18.92 | | |
|
Historical net tangible book value (deficit) per share as of September 30, 2022
|
| | | $ | (0.81) | | | | | | | | |
|
Increase in historical net tangible book value per share attributable to the pro forma adjustments described above
|
| | | | 6.40 | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2022
|
| | | | 5.59 | | | | | | | | |
|
Increase in pro forma as adjusted net tangible book value per share attributable to investors purchasing shares in this offering
|
| | | $ | 2.85 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share as of September 30, 2022 after
giving effect to this offering |
| | | | | | | | | $ | 8.44 | | |
|
Dilution per share to investors purchasing shares in this offering
|
| | | | | | | | | $ | 10.48 | | |
|
| TABLE OF CONTENTS | | | |||||
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 15 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 30 | | |
1 Year KALA BIO Chart |
1 Month KALA BIO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions